JPMorgan Chase & Co. Reaffirms Overweight Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reiterated by research analysts at JPMorgan Chase & Co. in a research report issued on Wednesday, MarketBeat.com reports.

Several other equities research analysts also recently issued reports on the company. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 140 ($1.77) target price on shares of AstraZeneca in a report on Monday, January 27th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average price target of GBX 7,542.80 ($95.58).

AstraZeneca Price Performance

Shares of LON:AZN opened at £115.90 ($146.86) on Wednesday. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The stock has a market capitalization of £223.00 billion, a P/E ratio of 31.77, a P/E/G ratio of 0.86 and a beta of 0.17. The business has a 50-day moving average of £109.74 and a two-hundred day moving average of £114.65. AstraZeneca has a fifty-two week low of GBX 9,670 ($122.53) and a fifty-two week high of £133.88 ($169.64).

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.